Clinical Trials
23 trialsNCT07495579 2026-05-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT07518706 2026-04-09
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07460206 2026-03-10
PRELUDE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT07432568 2026-02-25
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07417501 2026-02-18
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
Tongji Hospital
Phase 2 Not yet recruiting
NCT07412054 2026-02-17
BLP-HCC
Fudan University
Phase 2 Not yet recruiting
NCT07368985 2026-01-27
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
Erasmus Medical Center
Phase 2 Not yet recruiting
NCT07277972 2025-12-11
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05106127 2025-12-08
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
Evergreen Therapeutics, Inc.
Phase 2 Not yet recruiting
NCT07263360 2025-12-04
Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07159217 2025-09-08
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT07131501 2025-08-20
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06984718 2025-05-22
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
Akeso
Phase 2 Not yet recruiting
NCT06919848 2025-04-09
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
Fudan University
Phase 2 Not yet recruiting
NCT06884982 2025-03-19
An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib
Northern Jiangsu People's Hospital
Phase 2 Not yet recruiting
NCT05195294 2025-03-10
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
Lion TCR Pte. Ltd.
Phase 2 Not yet recruiting
NCT06849492 2025-02-27
SHIFT-001
Fudan University
Phase 2 Not yet recruiting
NCT06748508 2024-12-27
FDZL-GC003
Fudan University
Phase 2 Not yet recruiting
NCT06648525 2024-10-18
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
Harbin Medical University
Phase 2 Not yet recruiting
NCT06563934 2024-08-21
Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)
Shenzhen Third People's Hospital
Phase 2 Not yet recruiting
NCT06389500 2024-04-29
HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT06253598 2024-03-07
Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma
The First Affiliated Hospital of Bengbu Medical University
Phase 2 Not yet recruiting
NCT06028633 2023-09-13
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
Peking University First Hospital
Phase 2 Not yet recruiting